From Immunity to Oncology: Itaconic Acid as a Driver in HBV-Induced HCC.
作者信息
Mahmoudvand Shahab, Sheikhrobat Sheida Behzadi, Shokri Somayeh, Baghi Hossein Bannazadeh
机构信息
Infectious Disease Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Department of Virology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
出版信息
J Cell Mol Med. 2025 Jun;29(12):e70612. doi: 10.1111/jcmm.70612.
Abstract
摘要
相似文献
1
From Immunity to Oncology: Itaconic Acid as a Driver in HBV-Induced HCC.
J Cell Mol Med. 2025 Jun;29(12):e70612. doi: 10.1111/jcmm.70612.
2
Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature.
Rev Med Virol. 2022 Nov;32(6):e2353. doi: 10.1002/rmv.2353. Epub 2022 Apr 20.
3
Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations.
J Biomed Sci. 2018 Jun 2;25(1):51. doi: 10.1186/s12929-018-0442-4.
4
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340.
5
Epidemiology of viral hepatitis in Somalia: Systematic review and meta-analysis study.
World J Gastroenterol. 2018 Sep 14;24(34):3927-3957. doi: 10.3748/wjg.v24.i34.3927.
6
Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis.
Int J Cancer. 2011 Jan 1;128(1):176-84. doi: 10.1002/ijc.25321.
7
Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence.
Oncogene. 2006 Jun 26;25(27):3756-70. doi: 10.1038/sj.onc.1209557.
8
Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis.
PLoS One. 2012;7(9):e44611. doi: 10.1371/journal.pone.0044611. Epub 2012 Sep 5.
9
Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis.
Cochrane Database Syst Rev. 2017 Mar 21;3(3):CD011645. doi: 10.1002/14651858.CD011645.pub2.
10
Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors.
Ther Adv Med Oncol. 2025 Jun 19;17:17588359251347469. doi: 10.1177/17588359251347469. eCollection 2025.
本文引用的文献
1
Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition.
Hepatology. 2025 Sep 1;82(3):739-754. doi: 10.1097/HEP.0000000000001202. Epub 2024 Dec 19.
2
A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection.
Nature. 2024 Jul;631(8022):867-875. doi: 10.1038/s41586-024-07630-7. Epub 2024 Jul 10.
3
Control of immune cell signaling by the immuno-metabolite itaconate.
Front Immunol. 2024 Feb 28;15:1352165. doi: 10.3389/fimmu.2024.1352165. eCollection 2024.
4
Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8 T-cell exhaustion.
Nat Commun. 2023 Dec 9;14(1):8154. doi: 10.1038/s41467-023-43988-4.
5
The yin and yang of itaconate metabolism and its impact on the tumor microenvironment.
Curr Opin Biotechnol. 2023 Dec;84:102996. doi: 10.1016/j.copbio.2023.102996. Epub 2023 Oct 6.
6
Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming.
Nat Commun. 2023 Feb 27;14(1):984. doi: 10.1038/s41467-023-36594-x.
7
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.
J Virol. 2003 Jan;77(1):68-76. doi: 10.1128/jvi.77.1.68-76.2003.
Zotero 插件